---
granola_id: 6576cb6f-123d-4b69-bbaa-29db309b64ab
title: "Rabi Alam and Emre Karatas"
type: note
created: 2025-06-24T18:10:38.796Z
updated: 2025-07-10T23:18:00.294Z
attendees:
  - rabi@counterhealth.com
  - sd@virtuevc.com
---
### Key Metrics & Growth

- $1M left on $14M post-money valuation
- Revenue grew from $100k to $800k
- 85% of groups closed by resellers with zero lift from Counter
- Pipeline with warm opportunities expanded from $100k to $4.5M (15% of book)
- Latest employer closed is 5x larger than largest employer from previous year
- 6:1 average ROI across 37 employers
- 2-week payback period for employers

### Partnership Strategy & Distribution

- Houston Clinic pilot through RxConnection (broker and pharmacy benefit consultant)
- ProAct (PBM) partnership developed through RxConnection relationship
- ProAct sees Counter as innovation differentiator for RFPs
- Implementation timeline improved significantly:
	- First PBM implementation took several months
	- Subsequent PBM implementations (Maxor, ProCare, EHI) now take 2-3 weeks
	- Plan sponsor implementations now take ~3 weeks

### Savings Mechanisms & Clinical Focus

- Core savings drivers:
	- Find lower cost clinical alternatives
	- Lower cost pharmacies
	- Funding assistance programs (including co-pay accumulator programs - noted as “cat and mouse”)
- Savings concentration:
	- 2% of spend driving 95% of excess spend
	- Focus on high-cost branded medications and specialty drugs
- Key therapeutic areas showing strong outcomes:
	- Anti-inflammatory (Humira biosimilars, RINVOQ)
	- Anti-asthmatic (branded to generic inhaler transitions)
	- Cardiovascular (Eliquis, Jardiance)
	- Behavioral health (unexpected success area)

### Technical Implementation

- Re-adjudicating claims to identify savings opportunities
- Integrates multiple data sources:
	- Claims data
	- Formulary plan design
	- Client-specific edits
	- MAC lists from PBMs
	- Third-party pricing
- Clinical alternatives developed with advisors:
	- Rory Davies (interim Chief Pharmacy Officer at Cigna)
	- Craig Fisher (VP of Clinical, ex-Walgreens)

### Strategic Opportunities

- Cigna partnership advancing:
	- Moving into procurement phase
	- Headcount allocation in progress
	- Planning first groups for late 2023/early 2024
	- Potential to capture 33-35% of pharmacy care navigation market
- Product accessibility:
	- Built as responsive website vs app
	- No signup required
	- Multi-channel engagement (calls, SMS, email, direct mail)
	- Proactive outreach model

Chat with meeting transcript: https://notes.granola.ai/d/6576cb6f-123d-4b69-bbaa-29db309b64ab
